Serum GFAP antibodies are now used as a predictive marker for the development of T1D, and it has been shown that administration of GFAP as a vaccine delayed the progression of T1D by regulating T cell differentiation (22, 23). Here, GFAP is linked to type 1 diabetes mellitus.